A Multi-centre, Randomized, Double-blind, Placebo and Active Controlled, Parallel-arm study to evaluate the efficacy of LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI), in patients with systolic hypertension.
Phase of Trial: Phase II
Latest Information Update: 28 Oct 2014
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Hypertension
- Focus Therapeutic Use
- 28 Oct 2014 New trial record